Precision Medicine in Oncology®

An interview with Brian Rini, MD, whose research has focused on RCC, prostate, and other genitourinary cancers, as well as on antiangiogenic therapy and immunotherapy.

A pilot study has demonstrated a lag in the integration of genetics and genomics into nursing practice, which is an increasingly required professional skill for oncology nurses.

Many targeted therapies are associated with dermatologic side effects; the monitoring and treating of these side effects should be done on an individual patient basis.

Dr. Neil Spector, from Duke Cancer Institute, Emphasizes the Importance of Studying Tumor Microenvironments

Researchers have determined that breast cancer can be classified into 10 different subtypes instead of four subtypes as previously thought.

Leonard M. Neckers, PhD, has been studying the role of the molecular chaperone Hsp90 in signal transduction and the translational development of Hsp90-targeted anticancer agents for two decades.

Hsp90 may be referred to as the 'guardian of the proteome,' since it regulates the correct structure and function of many of the important proteins encoded by our DNA.

Dr. Edith Perez, from the Mayo Clinic, Describes the Breast Cancer Translational Genomics Program

Before the oncology treatment paradigm can move from a one-size-fits-all model to true personalized medicine, the medical establishment must find a cost-effective way to identify biomarkers.

The long-sought aim of treating malignant disease by targeting particular molecular abnormalities is becoming a reality in an increasing number of clinical settings.

The USC Norris Comprehensive Cancer Center and Hospital has long enjoyed a national reputation as a leading resource for cancer research, treatment, prevention, and education.

Agents that target the c-MET pathway may prove to have significant benefit when combined with inhibitors of angiogenesis.

The keynote address at the ASCO Genitourinary Cancers Symposium highlighted a collaborative effort to develop a comprehensive molecular classification of prostate cancer.

Optical biomarkers derived from nondysplastic metaplastic cells can detect the presence of high-grade dysplasia and adenocarcinoma from Barrett's esophagus.

Dr. Neil Spector, from Duke Cancer Institute, Discusses the Systemic Nature of Cancer

This issue of Contemporary Oncology includes a focus on 2 challenging situations: management of metastatic TNBC and of advanced stage NSCLC.

The use of advanced gene analysis techniques in a small group of women with triple-negative metastatic breast cancer has revealed activity in two pathways found in most patients with this subtype.

As research progresses, optimal treatment of breast cancer will involve individualization of therapy to focus on specific targets driving each patient's cancer.

Dr. Charles Perou, from the UNC Lineberger Comprehensive Cancer Center, on Next Generation Sequencing Technology

Dr. Andrew Zelenetz, from Memorial Sloan-Kettering Cancer Center, on Targeted Therapies for Diffuse Large B-cell Lymphoma

Dr. Matthew Ellis, from Siteman Cancer Center, Describes Breast Cancer Heterogeneity

HER2 status in patients with breast cancer has emerged as a durable and effective marker for evaluating tumors and selecting therapies.

Researchers are reporting better survival rates in women with invasive EOC and germline mutations in the tumor suppressor genes BRCA1 and BRCA2 than in patients who are noncarriers.

Dr. Neil Spector, from the Duke Cancer Institute, Discusses the Complexities of Cancer

Dr. Kieron Dunleavy, from the National Cancer Institute, Discusses ABC DLBCL Research